Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
Nina D. Wagner-Johnston
Research Funding - Gilead Sciences
Ajay K. Gopal
Research Funding - Gilead Sciences (I)
Brad S. Kahl
Research Funding - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences
Stephen J. Schuster
Research Funding - Gilead Sciences
Wojciech Jurczak
Research Funding - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Christopher Flowers
Research Funding - Gilead Sciences
Peter Martin
Research Funding - Gilead Sciences
Andreas Viardot
Research Funding - Gilead Sciences
Kristie A. Blum
Research Funding - Gilead Sciences
Andre Goy
Research Funding - Gilead Sciences
Andrew John Davies
Research Funding - Gilead Sciences
Pier Luigi Zinzani
Research Funding - Gilead Sciences
Martin H. Dreyling
Research Funding - Gilead Sciences
Lynne I. Wagner
Research Funding - Gilead Sciences
Bess Sorensen
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Wayne Russell Godfrey
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Gilles A. Salles
Research Funding - Gilead Sciences